France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund
The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.
You may also be interested in...
The French pharmaceutical industry association is cautiously optimistic that the new government will take a longer-term view of the industry’s contribution to healthcare, and has proposed a pact setting out the relations between the industry and the state.
The French health ministry is hoping a new campaign aimed at increasing the use of generics and dispelling any remaining doubts about their quality among the public will bring cost savings.
The French regulatory agency ANSM has relaxed its stance on biosimilar interchangeability to state that while in principle patients should preferably not be switched between a reference drug and a biosimilar during their course of treatment, this can be done provided the patient agrees and their treatment is closely monitored1.